Next-level medicine with ease – powered by moss.

Next-level biologics are increasingly based on large molecules with intricate glycosylation patterns and several post-translational modifications. As the complexity of these medicines increases, so does the challenge of finding enabling technologies capable of managing this complexity from idea to product.

Eleva generates value by unlocking and developing unique therapies. The company is uniquely positioned to address molecular challenges with its proprietary moss-based technology and expertise.

We substantiate this claim by developing a portfolio of therapeutic candidates independently into clinical development and attract partners for de novo projects. Factor H (CPV-104), our recombinant version of human complement Factor H, is progressing through clinical studies in severe, complement-driven kidney diseases including C3 Glomerulopathy (C3G). Our recombinant version of a-galactosidase aGal (RPV-001) has already delivered promising initial clinical data in Fabry disease.

All programs are sourced from Eleva’s transformative moss-based technology, which provides access to challenging proteins and therapeutic modalities with refined and optimized product characteristics. We believe, there are many opportunities in our industry across a range of indications, that would benefit from Eleva’s capabilities right from the start and throughout their entire product development journey.